DK3126361T3 - Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer - Google Patents

Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer Download PDF

Info

Publication number
DK3126361T3
DK3126361T3 DK15714951.9T DK15714951T DK3126361T3 DK 3126361 T3 DK3126361 T3 DK 3126361T3 DK 15714951 T DK15714951 T DK 15714951T DK 3126361 T3 DK3126361 T3 DK 3126361T3
Authority
DK
Denmark
Prior art keywords
chromen
dions
tetrahydrocyclopropa
pyridopyrazine
gamma secretase
Prior art date
Application number
DK15714951.9T
Other languages
English (en)
Inventor
Ende Christopher William Am
John Michael Humphrey
Douglas Scott Johnson
Gregory Wayne Kauffman
Martin Youngjin Pettersson
Danica Antonia Rankic
Antonia Friederike Stepan
Patrick Robert Verhoest
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3126361(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of DK3126361T3 publication Critical patent/DK3126361T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK15714951.9T 2014-04-01 2015-03-18 Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer DK3126361T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01
PCT/IB2015/051988 WO2015150957A1 (en) 2014-04-01 2015-03-18 Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators

Publications (1)

Publication Number Publication Date
DK3126361T3 true DK3126361T3 (da) 2020-01-02

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15714951.9T DK3126361T3 (da) 2014-04-01 2015-03-18 Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer

Country Status (30)

Country Link
US (2) US20150274721A1 (da)
EP (1) EP3126361B1 (da)
JP (1) JP6643247B2 (da)
KR (1) KR101886945B1 (da)
CN (1) CN106211770B (da)
AP (1) AP2016009465A0 (da)
AR (1) AR099874A1 (da)
AU (1) AU2015242330B2 (da)
BR (1) BR112016022519A8 (da)
CA (1) CA2944308A1 (da)
CL (1) CL2016002422A1 (da)
CR (1) CR20160454A (da)
CU (1) CU20160140A7 (da)
DK (1) DK3126361T3 (da)
DO (1) DOP2016000266A (da)
EA (1) EA031419B1 (da)
EC (1) ECSP16078289A (da)
ES (1) ES2759277T3 (da)
HK (1) HK1231481A1 (da)
IL (1) IL248154B (da)
MD (1) MD20160102A2 (da)
MX (1) MX369074B (da)
NI (1) NI201600149A (da)
PE (1) PE20161364A1 (da)
PH (1) PH12016501864A1 (da)
SG (1) SG11201607465UA (da)
TW (1) TWI568733B (da)
UY (1) UY36054A (da)
WO (1) WO2015150957A1 (da)
ZA (1) ZA201606252B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
PE20171318A1 (es) * 2015-02-03 2017-09-07 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии
CN112996789A (zh) * 2018-09-12 2021-06-18 诺华股份有限公司 抗病毒吡啶并吡嗪二酮化合物
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
AU2020353055B2 (en) 2019-09-26 2024-03-07 Gilead Sciences, Inc. Antiviral pyrazolopyridinone compounds
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
JP3816111B2 (ja) 1997-04-09 2006-08-30 インテレクト・ニューロサイエンシズ・インコーポレーテッド β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
BRPI0108676B8 (pt) 2000-02-24 2021-05-25 Lilly Co Eli anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
EP1335738A4 (en) 2000-11-03 2004-09-08 Proteotech Inc METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS
EP1432444A4 (en) 2001-08-17 2005-11-02 Lilly Co Eli ANTI-BETA ANTIBODIES
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
BR0308109A (pt) * 2002-02-28 2005-01-04 Sanofi Aventis Derivados 2-piridinil e 2-pirimidinil-6,7,8,9-tetraidro-pirimido[1,2-a] pirimidin-4-ona substituìdos com hetero arila
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
EP1633786A4 (en) 2002-10-09 2007-07-25 Rinat Neuroscience Corp METHOD FOR TREATING ALZHEIMER DISEASE WITH ANTIBODIES TO AMYLOID BETA PEPTIDE AND COMPOSITIONS THEREOF
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
BRPI0410630A (pt) 2003-06-19 2006-06-13 Pfizer Prod Inc antagonista de nk1
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
BRPI0507374A (pt) 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
EP2298807A3 (en) 2004-07-30 2011-05-18 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
WO2006069081A2 (en) 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
US7812040B2 (en) 2005-06-22 2010-10-12 Pfizer Inc. Histamine-3 receptor antagonists
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
CA2624625A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
AU2007242555B2 (en) 2006-04-21 2010-12-16 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
PT2124933E (pt) 2007-01-22 2013-01-07 Pfizer Prod Inc Sal tosilato de um composto terapêutico e composições farmacêuticas do mesmo
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式ｍ１受容体ポジティブアロステリック調節因子
WO2012131539A1 (en) * 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
AU2013261023B2 (en) * 2012-05-16 2016-11-24 Cellzome Limited Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
EP2945944B1 (en) * 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
CA2925743C (en) * 2013-10-04 2018-03-06 Pfizer Inc. Novel bicyclic pyridinones as gamma-secretase modulators

Also Published As

Publication number Publication date
EP3126361A1 (en) 2017-02-08
ES2759277T3 (es) 2020-05-08
TWI568733B (zh) 2017-02-01
MX2016012904A (es) 2016-12-07
CR20160454A (es) 2016-12-06
BR112016022519A8 (pt) 2018-03-06
ZA201606252B (en) 2018-05-30
MX369074B (es) 2019-10-28
EP3126361B1 (en) 2019-11-06
CN106211770B (zh) 2018-02-06
EA201600619A1 (ru) 2017-03-31
AU2015242330A1 (en) 2016-09-22
AP2016009465A0 (en) 2016-09-30
KR101886945B1 (ko) 2018-08-08
MD20160102A2 (ro) 2017-04-30
SG11201607465UA (en) 2016-10-28
TW201540716A (zh) 2015-11-01
AU2015242330B2 (en) 2017-08-17
ECSP16078289A (es) 2017-02-24
CN106211770A (zh) 2016-12-07
US20170166566A1 (en) 2017-06-15
EA031419B1 (ru) 2018-12-28
HK1231481A1 (zh) 2017-12-22
US20150274721A1 (en) 2015-10-01
BR112016022519A2 (pt) 2017-08-15
KR20160137635A (ko) 2016-11-30
CL2016002422A1 (es) 2017-02-03
CU20160140A7 (es) 2017-02-02
AR099874A1 (es) 2016-08-24
PH12016501864A1 (en) 2016-12-19
WO2015150957A1 (en) 2015-10-08
JP2017512803A (ja) 2017-05-25
IL248154A0 (en) 2016-11-30
CA2944308A1 (en) 2015-10-08
IL248154B (en) 2020-09-30
UY36054A (es) 2015-10-30
PE20161364A1 (es) 2016-12-25
NI201600149A (es) 2016-11-18
JP6643247B2 (ja) 2020-02-12
DOP2016000266A (es) 2016-11-15

Similar Documents

Publication Publication Date Title
DK3126361T3 (da) Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer
DK3490565T3 (da) Azetidinderivater som chemokinreceptormodulatorer og anvendelser deraf
DK3307707T3 (da) Halogensubstituerede phenoxyphenylamidiner og anvendelsen deraf som fungicider
EP3262022A4 (en) Phenylethynylnaphthalene dyes and methods for their use
MA53943A (fr) Modulateurs de ror-gamma
EP3268434A4 (en) UV ABSORBENT POLYMER DYES AND METHOD OF USE THEREOF
EP3334900A4 (en) Borehole testing device
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
EP3110850A4 (en) Deep eutectic solvents and their use
DK3129366T3 (da) Carbazol-indeholdende amider, carbamater og urinstoffer som kryptokrommodulatorer
EP3122721A4 (en) Ror-gamma modulators and uses thereof
EP3317277A4 (en) Somatostatin modulators and uses thereof
EP3154972A4 (en) Azamophinan derivatives and use thereof
DK3319963T3 (da) Substituerede 4-azaindoler og deres anvendelse som glun2b receptormodulatorer
PT3303291T (pt) Moduladores de ror gama
PT3303293T (pt) Moduladores ror-gama
EP3097088A4 (en) Icariin derivatives
HK1226054A1 (zh) 作為mglur4調節劑的乙炔基咪唑烷 2，4 二酮衍生物
ZA201607552B (en) Modular bridge and bridge module
AU2015343095B2 (en) Application testing
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
EP3128996A4 (en) Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
EP3400209A4 (en) ASCOCHLORIN DERIVATIVE AND ITS USE AS AMPK ACTIVATOR
EP3383401A4 (en) THIENO-PYRIMIDINE DERIVATIVES AND USES THEREOF
EP3414313A4 (en) MICRO CAPSULE